Patent details
301322
Product Name:
Repotrectinib en/of farmaceutisch aanvaardbare zouten daarvan
The time of generation of the report may vary depending on the number of the selected files and the pages of each file. If the generation of the consolidated PDF file takes long, you may reduce the number of selected files and proceed with the generation of the PDF in batches.
Ok
Cancel
You have not selected any documents
Ok
Basic Information
Publication number:
301322
Type:
Certificate
SPC Type:
Medical
Basic Patent Number:
EP3572416
Status:
SPC granted but not yet in force
Application number:
301322
Procedural language:
Dutch
First Applicant Residence Country:
United States of America (US)
Marketing Authorization
Marketing Authorization Number:
EU/1/24/1883
Marketing Authorization Type:
EEA
Marketing Authorization Date:
14/01/2025
Marketing Authorization Country:
European Union (EU)
Dates
Filing date:
12/03/2025
First Marketing Authorization date:
14/01/2025
Grant date:
27/05/2025
Activation date:
Lapsed By Non Payment Annual Fee Date:
Renunciation Date:
NullificationDate:
Registration date:
13/03/2025
SPC/SPC Extension Expiration Date:
13/01/2040
Lapsed By Expiration Date:
Withdrawal date:
Revocation Date:
Invalidity Date:
Withdrawal Market Authorization Date:
Refusal Date:
Applicant/holder
From:
17/03/2025
Name:
Turning Point Therapeutics, Inc.
Address:
Route 206 and Province Line Road, 08543, Princeton, NJ, United States of America (US)
Agent
Name:
dr. R.C. van Duijvenbode c.s.
From:
12/03/2025
Address:
NLO
Postbus 29720, 2502 LS, Den Haag, Netherlands (NL)
To:
Publication
Bulletin
1
Bulletin Heading:
SPC
Journal edition number:
22/25
Publication date:
28/05/2025
Description:
Applications and granted Supplementary Protection Certificates (or the extensions of the Supplementary Protection Certificates)
2
Bulletin Heading:
SPC
Journal edition number:
12/25
Publication date:
19/03/2025
Description:
Applications and granted Supplementary Protection Certificates (or the extensions of the Supplementary Protection Certificates)
Annual Fee
Annual Fee(s) Due Date:
31/01/2035
Annual Fee Number:
21
Annual Fee Amount:
1600 Euro
Last Annual Payment Date:
Last Annual Fee Paid Number:
Payer:
Filing date
Document type
Document Description
Number of pages
File Type
27/05/2025
Outgoing Correspondence
Decision grant
1
PDF
/7/8/6/5/9/0801095687/docs/301322_8_658603l504a.pdf
27/05/2025
Certificate
Certificate
1
PDF
/7/8/6/5/9/0801095687/docs/301322_9_spcmedcertificate20250527130311109.pdf
26/05/2025
Incoming Correspondence Electronic
Accompanying letter incoming document
1
PDF
/7/8/6/5/9/0801095687/docs/301322_7_incomingcorrespondenceelectronic20250526122519751.pdf
17/04/2025
Outgoing Correspondence
Letter to applicant
2
PDF
/7/8/6/5/9/0801095687/docs/301322_6_652702l173.pdf
17/03/2025
Outgoing Correspondence
Confirmation receipt request
2
PDF
/7/8/6/5/9/0801095687/docs/301322_0_647989l174.pdf
12/03/2025
Application Form
First filed application form
2
PDF
/7/8/6/5/9/0801095687/docs/301322_1_applicationform20250313120640739.pdf
12/03/2025
SPC Documents
Annex SPC
1
PDF
/7/8/6/5/9/0801095687/docs/301322_2_supplprotectioncertificate20250313120722790.pdf
12/03/2025
SPC Documents
Annex SPC
1
PDF
/7/8/6/5/9/0801095687/docs/301322_3_supplprotectioncertificate20250313120700201.pdf
12/03/2025
SPC Documents
Marketing Authorization SPC
3
PDF
/7/8/6/5/9/0801095687/docs/301322_4_supplprotectioncertificate20250313120924566.pdf
12/03/2025
SPC Documents
Summary of the characteristics of the product
24
PDF
/7/8/6/5/9/0801095687/docs/301322_5_supplprotectioncertificate20250313120908178.pdf